Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[First experiences with BS 100-141, a new antihypertensive substance]

I Esch

    International Journal of Clinical Pharmacology and Biopharmacy
    |September 1, 1976
    PubMed
    Summary

    A new guanidine derivative, BS 100-141, significantly reduced blood pressure in patients. This novel antihypertensive agent proved more effective than alpha-methyl-DOPA, with minimal impact on blood glucose levels.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A randomized trial comparing the impact of a nonionic (Iomeprol) versus an ionic (Ioxaglate) low osmolar contrast medium on abrupt vessel closure and ischemic complications after coronary angioplasty.

    Journal of the American College of Cardiology·1999
    Same author

    [Plasma renin activity in essential hypertension: different short- und long-term effects of diuretics (author's transl)].

    Wiener klinische Wochenschrift·1976
    Same author

    [The question of indication for surgery in renovascular hypertension].

    Acta medica Austriaca·1975
    Same author

    [Renin grouping in essential hypertension: a comparison of various conditions of stimulation (author's transl)].

    Wiener klinische Wochenschrift·1974
    Same author

    [Longitudinal studies in essential hypertensive patients with low plasma renin activity].

    Wiener klinische Wochenschrift·1973
    Same author

    [Treatment of essential hypertension with spironolactone with reference to the plasma renin activity].

    Wiener klinische Wochenschrift·1973

    Area of Science:

    • Pharmacology
    • Cardiovascular Medicine
    • Clinical Trials

    Background:

    • Hypertension remains a significant global health concern.
    • Existing antihypertensive medications have varying efficacy and side effect profiles.
    • Novel therapeutic agents are continuously sought to improve blood pressure management.

    Purpose of the Study:

    • To evaluate the efficacy and safety of a new guanidine derivative, BS 100-141, as an antihypertensive agent.
    • To compare the blood pressure-lowering effects of BS 100-141 with a standard antihypertensive drug, alpha-methyl-DOPA.
    • To assess the impact of BS 100-141 on blood glucose levels.

    Main Methods:

    • A clinical trial involving 20 patients with hypertension.
    • Administration of the guanidine derivative BS 100-141.
    • Comparative analysis against alpha-methyl-DOPA in a crossover design.
    • Monitoring of blood pressure and blood glucose concentrations.

    Main Results:

    • BS 100-141 demonstrated a statistically highly significant reduction in blood pressure.
    • BS 100-141 was more effective in lowering arterial pressure compared to alpha-methyl-DOPA, particularly in the later treatment phase.
    • A slight, non-clinically significant increase in blood glucose was observed in most patients treated with BS 100-141.

    Conclusions:

    • BS 100-141 is a potent antihypertensive agent with superior efficacy to alpha-methyl-DOPA.
    • The drug exhibits a favorable safety profile with minimal effects on glycemic control.
    • BS 100-141 represents a promising new therapeutic option for managing hypertension.

    Related Experiment Videos